AAAAAA
Results: 1-25/32
Authors:
Lippman, ME
Hayes, DF
Citation: Me. Lippman et Df. Hayes, Adjuvant therapy for all patients with breast cancer?, J NAT CANC, 93(2), 2001, pp. 80-82
Authors:
Hayes, DF
Yamauchi, H
Broadwater, G
Cirrincione, CT
Rodrigue, SP
Berry, DA
Younger, J
Panasci, LL
Millard, F
Duggan, DB
Norton, L
Henderson, IC
Citation: Df. Hayes et al., Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and leukemia group B study 8662, CLIN CANC R, 7(9), 2001, pp. 2703-2711
Authors:
George, DJ
Halabi, S
Shepard, TF
Vogelzang, NJ
Hayes, DF
Small, EJ
Kantoff, PW
Citation: Dj. George et al., Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer andleukemia group B 9480, CLIN CANC R, 7(7), 2001, pp. 1932-1936
Authors:
Fertig, DL
Hayes, DF
Citation: Dl. Fertig et Df. Hayes, Considerations in using tumor markers: What the psycho-oncologist needs toknow, PSYCHO-ONC, 10(5), 2001, pp. 370-379
Authors:
Hayes, DF
Citation: Df. Hayes, Dose intensity for breast cancer - The Armstrong/Davidson article reviewed, ONCOLOGY-NY, 15(6), 2001, pp. 712-714
Authors:
Yamauchi, H
Stearns, V
Hayes, DF
Citation: H. Yamauchi et al., When is a tumor marker ready for prime time? A case study of c-erbB-2 as apredictive factor in breast cancer, J CL ONCOL, 19(8), 2001, pp. 2334-2356
Authors:
Bast, RC
Ravdin, P
Hayes, DF
Bates, S
Fritsche, H
Jessup, JM
Kemeny, N
Locker, GY
Mennel, RG
Somerfield, MR
Citation: Rc. Bast et al., 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology, J CL ONCOL, 19(6), 2001, pp. 1865-1878
Authors:
Bast, RC
Ravdin, P
Hayes, DF
Bates, S
Fritsche, H
Jessup, JM
Kemeny, N
Locker, GY
Mennel, RG
Somerfield, MR
Citation: Rc. Bast et al., 2000 update of recommendations for the use of tumor markets in breast and colorectal cancer: Clinical practice guidelines for the American Society ofClinical Oncology (vol 19, pg 1865, 2001), J CL ONCOL, 19(21), 2001, pp. 4185-4188
Authors:
Kantoff, PW
Halabi, S
Farmer, DA
Hayes, DF
Vogelzang, NA
Small, EJ
Citation: Pw. Kantoff et al., Prognostic significance of reverse transcriptase polymerase chain reactionfor prostate-specific antigen in men with hormone-refractory prostate cancer, J CL ONCOL, 19(12), 2001, pp. 3025-3028
Authors:
Isaacs, C
Stearns, V
Hayes, DF
Citation: C. Isaacs et al., New prognostic factors for breast cancer recurrence, SEMIN ONCOL, 28(1), 2001, pp. 53-67
Authors:
Bok, RA
Halabi, S
Fei, DT
Rodriquez, CR
Hayes, DF
Vogelzang, NJ
Kantoff, P
Shuman, MA
Small, EJ
Citation: Ra. Bok et al., Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study, CANCER RES, 61(6), 2001, pp. 2533-2536
Authors:
Akewanlop, C
Watanabe, M
Singh, B
Walker, M
Kufe, DW
Hayes, DF
Citation: C. Akewanlop et al., Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody, CANCER RES, 61(10), 2001, pp. 4061-4065
Authors:
Guidi, AJ
Berry, DA
Broadwater, G
Perloff, M
Norton, L
Barcos, MP
Hayes, DF
Citation: Aj. Guidi et al., Association of angiogenesis in lymph node metastases with outcome of breast cancer, J NAT CANC, 92(6), 2000, pp. 486-492
Authors:
Thomssen, C
Janicke, F
Kaufmann, M
Scharl, A
Hayes, DF
Citation: C. Thomssen et al., Do we need better prognostic factors in node-negative breast cancer? Pro, EUR J CANC, 36(3), 2000, pp. 293-298
Authors:
Hayes, DF
Citation: Df. Hayes, Do we need better prognostic factors in node-negative breast cancer? Arbiter, EUR J CANC, 36(3), 2000, pp. 302-306
Authors:
Robins, JP
Rock, J
Hayes, DF
Laquer, FC
Citation: Jp. Robins et al., Nitrate removal for Platte valley, Nebraska synthetic groundwater using a constructed wetland model, ENV TECHNOL, 21(6), 2000, pp. 653-659
Authors:
Stearns, V
Isaacs, C
Rowland, J
Crawford, J
Ellis, MJ
Kramer, R
Lawrence, W
Hanfelt, JJ
Hayes, DF
Citation: V. Stearns et al., A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil (R)) in controlling hot flashes in breast cancer survivors, ANN ONCOL, 11(1), 2000, pp. 17-22
Authors:
Hayes, DF
Crockett, TR
Ward, TJ
Averett, D
Citation: Df. Hayes et al., Sediment resuspension during cutterhead dredging operations, J WATERW P, 126(3), 2000, pp. 153-161
Authors:
Baidas, SM
Winer, EP
Fleming, GF
Harris, L
Pluda, JM
Crawford, JG
Yamauchi, H
Isaacs, C
Hanfelt, J
Tefft, M
Flockhart, D
Johnson, MD
Hawkins, MJ
Lippman, ME
Hayes, DF
Citation: Sm. Baidas et al., Phase II evaluation of thalidomide in patients with metastatic breast cancer, J CL ONCOL, 18(14), 2000, pp. 2710-2717
Authors:
Hayes, DF
Citation: Df. Hayes, Designing tumor marker studies - Will the results provide clinically useful information, ARCH PATH L, 124(7), 2000, pp. 952-954
Authors:
Fitzgibbons, PL
Page, DL
Weaver, D
Thor, AD
Allred, C
Clark, GM
Ruby, SC
O'Malley, F
Sinpson, LF
Connolly, JL
Hayes, DF
Edge, SB
Lichter, A
Schnitt, SJ
Citation: Pl. Fitzgibbons et al., Prognostic factors in breast cancer - College of American Pathologists Consensus Statement 1999, ARCH PATH L, 124(7), 2000, pp. 966-978
Authors:
Hayes, DF
Citation: Df. Hayes, Clinical importance of prognostic factors - Moving from scientifically interesting to clinically useful, PRINCIPLES OF MOLECULAR ONCOLOGY, 2000, pp. 29-44
Authors:
Ellis, MJ
Hayes, DF
Citation: Mj. Ellis et Df. Hayes, Refining breast cancer risk assessment with molecular markers: the next step?, J NAT CANC, 91(24), 1999, pp. 2067-2068
Authors:
Hayes, DF
Ellis, MJ
Isaacs, C
Citation: Df. Hayes et al., Mounting evidence for postmastectomy locoregional radiation therapy - The Marks/Hardenbergh/Prosnitz article reviewed, ONCOLOGY-NY, 13(8), 1999, pp. 1141
Authors:
Shapiro, CL
Ervin, T
Welles, L
Azarnia, N
Keating, J
Hayes, DF
Citation: Cl. Shapiro et al., Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer, J CL ONCOL, 17(5), 1999, pp. 1435-1441